

Research Journal of Pharmaceutical, Biological and Chemical Sciences

The Changes in the Serum, Liver, Kidney Protein and Genomic DNA Profiles in Rats Treated with 7,12-Dimethylbenz(A) Anthracene and *Plantago major* L.

Ismet Berber,^{1*} Suat Ekin,² Abdulkadir Levent,³ and Gokhan Oto⁴

¹Department of Biology, Faculty of Arts and Sciences, Sinop University, Sinop, Turkey.

²Department of Chemistry, Faculty of Sciences, YuzuncuYil University, Van, Turkey.

³Department of Chemistry, Faculty of Arts and Sciences, Batman University, Batman, Turkey.

⁴Department of Pharmacology, Medical Faculty, YuzuncuYil University, Van, Turkey.

ABSTRACT

In the study, the changes in the serum, liver, kidney protein and genomic DNA profiles in Wistar albino rats administrated to 7,12-dimethylbenz(a)anthracene (DMBA) and *Plantago major* L. were investigated. SDS-PAGE profiling of the serum proteins showed that the levels of two proteins molecular weighing 140.8 kDa and 46.8 kDa were significantly lower on the 0th day of treatment than on the 60th day of application in the groups. Furthermore, two proteins (34.5 and 22.3 kDa) were solely present in DMBA-treated liver cell lysates. On the contrary, the kidney protein profiles did not show significant banding variations in groups. Genomic DNA analysis also confirmed that DNA extracted from liver and kidney cells did not fragment in any of the groups after the 60th study day. The proteins 34.5 and 22.3 kDa in liver cell lysates at the 60th day in DMBA-treated group could be extra-prognostic indicators for severe DMBA toxicity.

Keywords: DMBA, *Plantago major* L., protein profiles, genomic DNA

*Corresponding author



INTRODUCTION

Polycyclic aromatic hydrocarbons (PAHs) are a group of chemical substances that are generated by incomplete burning of organic materials such as wood, coal, creosote, and crude oil. A main origin of PAHs and its derivatives is volcano, forest fires, industrial and domestic waste incineration and various human activities [1]. As a derivative of PAHs, 7,12-dimethylbenz(a)anthracene (DMBA) is a hazardous carcinogenic chemical for mammalian and other organisms [2, 3]. DMBA causes non-cancer side effects and several tumors in specific tissues such as kidneys, liver, spleen, mammary and adrenal glands [4]. The available genotoxicity data indicate that there is a correlation between the accumulation of DMBA in different tissues and the development of certain cancer incidences [2, 5].

DMBA and other tumor inducing agents form many electrophilic reactants which bind to nucleic acids [6, 7], leading to alteration in replication, transcription and causing tumor formation [8, 9]. DMBA also forms adducts with other cellular macromolecules, such as hemoglobin, globin, and some large serum proteins [10, 11]. Serum includes several soluble proteins beneficial for the processes of immunological and cancer studies. Biomarker proteins in serum can be provided useful diagnostic criteria in different tumor-induced carcinogenesis [12-14]. However, it is stressed that none of them only was a suitable indicator and diagnostic biomarker molecules.

It is known that DMBA induces potential malignant tumors in vital organs such as liver, kidney, brain and bladder. Especially, the liver is a vital organ of overall metabolism and liver tissue cells metabolize many potentially toxic compounds as *in vivo*. Therefore, the liver is the center of drug and xenobiotic substances detoxification [8, 15, 16].

Medicinal plants have been used by all civilizations from previous times to the present because of their healing effects. Ethnopharmacologic studies suggested that natural anti-carcinogenic compounds isolated from plants might be reduced to tumor formation induced by carcinogens [11, 18]. Many studies concerning therapeutic effects of various medicinal plant extracts have been published related to DMBA-induced carcinoma [19-23]. Furthermore, other studies reported that phenolic substances containing in plants can be eliminated to the toxic effects induced by DMBA [24]. *Plantago major* (PM) is a perennial vascular plant, growing in the country over the world. PM produces a number of biologically valuable chemical compounds such as; benzoic acid, ferulic acid, salicylic acid, p-coumaric acid, vanillic acid, baicalein, oleanolic acid and ursolic acid [25]. The aqueous extracts of the PM were used for treating a wide range of ailments (diarrhoea, dysentery, cancers, ulcers, bladder problems, gastrointestinal disorders [25, 26]. Additionally, some studies suggested that *Plantago* spp. extracts had inhibitor and cytotoxic effects on melanoma cell lines, breast adenocarcinoma, and Ehrlich ascites tumor cells [18, 27].

So far, we have conducted a few studies including levels of total sialic acid, lipid bound sialic acid, some trace elements, retinol, retinyl palmitate, β -carotene, α -tocopherol, vitamin C in rat serum treated with DMBA and *P. major* [28, 29]. According to our knowledge in this field, there has been no data related to effect on serum, liver and kidney protein profiles in the rats administered with PM and DMBA. Therefore, we investigated the expression levels and variations in liver and kidney tissue protein profiles. The purpose

of the investigation was to determine the differentiations in the serum, liver, kidney protein profiles and genomic DNA in Wistar albino rats subjected to DMBA and *P. major* aqueous extract.

MATERIALS AND METHODS

Plant Materials:

Plant samples of *Plantago major* were collected from Van, Turkey and identified and authenticated by the Department of Biology, Faculty of Art and Science, Yuzuncu Yil University, Van, Turkey. Plant material dried at room temperature. Dried plant material (300 mg) was infused in 30 mL of boiled distilled water for 30 min. After decantation and filtration, the filtrate was again dried in an incubator at 50 °C. Finally, the aqueous extract was prepared in isotonic physiological solution (0.9% NaCl) [30].

Animals:

Wistar albino rats were reared in a room with a constant temperature of 22 ± 1 °C, a relative humidity of $55 \pm 10\%$, and under the controlled light/dark cycles (12/12 h). Animals were maintained with free access to water and a standard laboratory diet. The study was performed on 18 Wistar albino rats. They were randomly separated into three groups of six animals each. Group 1 was used as the control ($n = 6$) and fed orally with olive oil (intragastrically). Rats in group 2 ($n = 6$) were treated orally with a single dose of DMBA (100 mg kg^{-1} body weight) in olive oil (intragastrically). Animals in Group 3 ($n = 6$) were treated orally with a single dose of DMBA (100 mg kg^{-1} body weight) in olive oil followed by aqueous extract of PM (100 mg kg^{-1} body weight) every day (intragastrically). The administrations were performed throughout 60 days for each group. All procedures were carried out in accordance with the conventional guidelines of the Local Institutional Committee, Van, Turkey, for experimentation with animals.

Preparation of Serum and Tissue Samples:

Blood samples were collected at the beginning of application (0th day) and on the 60th study day of administration by the intracardiac method and centrifuged at 500 rpm for 15 min to obtain the sera. Later, each the serum sample (20 μL) was transferred into an eppendorf tube, and adding 25 μL of SDS-sample buffer containing 0.006 M Tris-HCl, 2.5% glycerol, 0.5% SDS, and 1.25% β -mercaptoethanol (pH 6.8), and the mixture was stirred gently to ensure good homogenization. Then the serum proteins were denatured in a boiling water bath for 5 min., and the denatured proteins were stored at -70 °C until the electrophoresis was carried out. Liver and kidney samples following 60th study day were just excised and washed in ice-cold 1.15% KCl solution, dried using filter paper. Later, they homogenized in 5 folds of 50 mM Tris-HCl buffer (pH 7.5). After centrifugation at 12,100 rpm for 10 min., 25 μL of the supernatant was transferred into an eppendorf tube. Finally, 25 μL of denaturing buffer (0.006 M Tris-HCl, 2.5% glycerol, 0.5% SDS, and 1.25% β -mercaptoethanol, pH 6.8) added to the supernatant samples, and proteins were denatured in boiling water for 5 min. The denatured tissue proteins were kept at -70 °C until the electrophoresis was carried out.

SDS-PAGE of Serum and Tissue Proteins:

The serum and tissue proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 1 mm thick gel slabs (3.5 cm, 4% stacking and 15.5 cm, 12% resolving gels) as mentioned by Laemmli [31]. Electrophoresis was performed with a discontinuous buffer system in a UVP vertical electrophoresis unit (Cambridge, England). The gel was run at 30 mA until the bromophenol blue marker reached the bottom of the gel. Protein molecular weights were calculated by comparison with the following standards (PageRuler™ Protein Ladder SDS-PAGE Standards, Fermentas, molecular weights range 10-200 kDa). After electrophoresis, the gels were rinsed for 20 min. in 1:3:6 isopropanol-acetic acid-water solution and then for 5 min in 3:1:6 methanol-acetic acid-water solution. Finally, the gels were stained for 6 h in 0.01% (w/v) Coomassie Brilliant Blue R-250 followed by destaining in the 3:1:6 methanol-acetic acid-water mixture until the protein bands became clearly visible.

The gels were scanned via high resolution scanner (HP 3500 C Hewlett Packard Co.), and the molecular weight of each protein band was determined by one-dimensional analysis software (Total Lab 1D Manual R11.1, UK).

DNA Extraction and Agarose Gel Electrophoresis:

DNA extraction from liver and kidney tissues were carried out according to Sambrook et al. [32]. Extracted DNA was dissolved in loading buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 50 µg/mL RNase). DNA for each sample (5 µg) was loaded into 1% agarose gel in 89 mM Tris-borate, 89 mM boric acid and 2 mM EDTA pH 8.0. Genomic DNA subjected to electrophoresis at 100 V 2 h on a horizontal slab gel unit (Midicell® Primo Submarine Gel System, USA) and stained with ethidium bromide for photography under UV illuminator (Cedex, France).

RESULTS

SDS-PAGE profiles of serum proteins of the control group, DMBA-treated group and PM aqueous extract-treated group at the beginning of application and on the 60th study day are shown in Figure 1. The levels of two proteins molecular weighing 140.8 kDa and 46.8 kDa (marked as 2 and 6) were significantly higher on the 60th day of treatment than on the 0th day of application for whole groups. However, the levels of four proteins numbered by 1, 3, 4 and 5, respectively were not shown significantly a change both on the 0th and 60th study days following the administration for each group.

Figure 2 are shown the SDS-polyacrylamide gel protein profiles of liver and kidney tissues in the control group, DMBA-treated group and PM aqueous extract-treated group after the 60th study day. The results of SDS-PAGE analysis indicated that the high (186.2 kDa, numbered by 7) and the low (34.5 and 22.3 kDa, marked as 8 and 9) molecular weight polypeptides of liver were appeared only in DMBA-treated and PM+DMBA-treated groups. On the contrary, the levels of kidney protein profiles were not seen significantly banding variations for all groups.

Additionally, the results of agarose gel electrophoresis analysis showed that the genomic DNA of liver and kidney tissues not fragmented in the control group, DMBA-treated group and PM aqueous extract-treated group after the 60th study day (Figure 3).




Fig. 1. SDS-PAGE profiles of serum proteins of 1. Group (Control), 2. Group (DMBA) and 3. Group (DMBA+PM). Lines 1-5, 0th day; lines 6-10, 60th day, line 11, marker.




Fig. 2. SDS-PAGE profiles of liver and kidney tissue proteins of 1. Group (Control), 2. Group (DMBA) and 3. Group (DMBA+PM). Line 1, marker; lines 2-7 0th day; lines 8-13, 60th day.




Fig. 3. Genomic DNA profiles of 1. Group (Control), 2. Group (DMBA) and 3. Group (DMBA+PM). Lines 1, marker; lines 2-7 0th day; lines 8-13, 60th day.

DISCUSSION

As a derivative of polycyclic aromatic hydrocarbons (PAHs), 7,12-dimethylbenz(a)anthracene (DMBA) is one of the most important harmful and carcinogenic substance for humankind [2, 3]. The compound caused tumors in some specific tissues such as kidneys, liver, spleen, mammary and adrenal glands because of stored mostly in the sites [4]. In the present study, we investigated the changes in serum, liver and kidney tissue protein profiles and genomic DNA in Wistar albino rats administered to DMBA and *P. major*.

Serum contains a number of soluble proteins useful for the processes of immunological and cancer investigations. Biomarker proteins in serum can be provided useful diagnostic criteria in different tumor-induced carcinogenesis [12-14]. However, it is stressed that none of them solely was a suitable indicator and diagnostic biomarker molecules. In this study, SDS-PAGE profiling of the serum proteins showed that the levels of two proteins with molecular weights of 140.8 kDa and 46.8 kDa were significantly lower on the 0th day of treatment than on the 60th day of application in all groups. On the other hand, the levels of four proteins with molecular masses between 50-200 kDa did not change considerably in each group throughout all the administrations. Our findings confirmed that the expression levels of a few serum proteins changed in DMBA-induced toxicity in rats. However, it was also observed that the administration of *P. major* aqueous extract did not crucially affect the serum protein profiles of animals in Group 3 on the 0th and 60th study days. Our findings are in good agreement with previous studies [12, 14, 19, 21].

In recent years, a number of valuable papers including protective effects of aqueous extracts of different medicinal plants have been published about DMBA-induced carcinoma [4, 19-23]. The results of these studies revealed that there was a decrease in the level of the expression of some specific proteins and an increase in the expression of some proteins in various carcinogenesis induced by DMBA. Additionally, some studies suggested that *Plantago* spp. extracts had inhibitor and cytotoxic effects on melanoma cell lines, breast adenocarcinoma, and Ehrlich ascites tumor cells [18, 27]. It is well known that DMBA

induces potential malignant tumors in some vitally important special tissues such as skin, kidney, mammary, bladder, brain and liver. Therefore, we also investigated the expression levels and variations in liver and kidney tissue protein profiles.

The liver is one of the important organs of overall metabolism and liver tissue cells metabolize various potentially toxic compounds. Therefore, the liver is the center of drugs and xenobiotic substances detoxification [8]. Alterations in hepatic metabolism may affect the balance between the levels of detoxification products and carcinogenic metabolites [15, 16]. In the present study, two proteins (34.5 and 22.3 kDa) determined in DMBA-treated liver homogenates may be extra-prognostic indicators for DMBA toxicity. It was also evaluated that the presence of the protein molecular weighing 186.2 kDa in DMBA+PM group was incoherent. On the other hand, in the kidney protein profiles were not seen significantly banding variations among groups, in spite of the changes in the expression levels of some proteins.

The data gathered from many studies suggested that DMBA and similar tumor promoting agents formed various electrophilic reactants which bind tightly to nucleic acids [6, 7], leading to alteration in replication, transcription and causing tumor formation [8, 9]. In this study, we have not observed a significant change in the nuclear DNA isolated from liver and kidney cells for all three groups following the 60th study day. Our findings are agreed with partially Oommen et al. [33] and previous studies [8, 15].

In conclusion, our results suggested that the increases in the amount of the proteins weighing 140.8 kDa and 46.8 kDa in serum at the 60th day in DMBA-treated and DMBA+PM treated groups might be linked in developing DMBA toxicity. Additionally, the proteins weighing 34.5 and 22.3 kDa at the 60th day in DMBA-treated for liver homogenates could be extra-prognostic indicators for severe DMBA toxicity. However, we suggested that obtaining more accurate prognostic tools related to the DMBA toxicity will be necessary more comprehensive data.

ACKNOWLEDGEMENTS

The study was supported by a grant from the Scientific Research Projects Presidency of YuzuncuYil University (2008-FED-B083).

REFERENCES

- [1] Neef JM. Hemisphere Publication, NY, 1985, pp. 416-454.
- [2] Li N, Chen X, Liao J, Yang G, Wang S, Josephson Y, Han C, Chen J, Huang MT, Yang CS. *Carcinogenesis* 2003;23:1307-1313.
- [3] Nagar S, Zalatoris JJ, Blanchard RL. *Pharmacogenet* 2004;14(8):487-499.
- [4] Paliwal R, Sharma V, Pracheta S, Sharma S, Yadav S, Sharma S. *Biol Med* 2011;3(2):27-35.
- [5] Migliore L, Coppede F. *Mutation Res* 2002;512:135-153.
- [6] Slaga TJ, Gleason GL, Wells G. *Cancer Res* 1980;40:1981-1984.
- [7] Harry R. *Carcinogen* 2001;22:1903-1930.
- [8] Muqbil I, Banu N. *Cancer Lett* 2006;240:213-220.
- [9] Ekin S, Oto G, Berber I, Turel I, Kusman T. *Asian J Chem* 2008;20(7): 5704-5710.

- [10] Bechtold WE, et al. *J Appl Toxicol* 1991;11(2):115-118.
- [11] Krichah R, et al. *Polish J Environ Stud* 2003;12(5):589-594.
- [12] Furuta M, et al. *Oncogene* 2004;23(40):6806-6814.
- [13] Welsh JB, et al. *Proc Natl Acad Sci USA* 2003;100(69):3410-3415.
- [14] Elstner A, et al. *J Neurooncol* 2011;102:71-80.
- [15] Vater ST, Baldwin DM, Warshawsky D. *Cancer Res* 1991;51:492-498.
- [16] Al-AtharAM. *Pak J Nutr* 2004;5:304-309.
- [17] Tanaka T, Kohno H, Mori H. *Asian Pacific J Cancer Prevention* 2001;2:165-175.
- [18] Ozaslan M, Karagöz ID, Kalender ME, Kilic IH, Sarı I, Karagöz A. *The American J Chinese Med* 2007;35(5):841-851.
- [19] Balasenthil S, Rao KS, Nagini S. *Polish J Pharmacol* 2003;55:793-798.
- [20] Mirunalini S, Kumaragruparan R, Subapriya R, Nagini S. *Pharm Biol* 2004;42(3):240-245.
- [21] Samy RP, Gapalakrishnakone P, Ignacimuthu S. *Chemico-Biological Int* 2006;164:1-14.
- [22] Chaudhary G. *Int J Biol Med Res* 2011;2(3):671-678.
- [23] Purushothaman A, Nandhakumar E, Sachdanandam P. *Asian J Pharm Clin Res* 2012;5:101-107.
- [24] Ignatowicz E, Balana B, Vulimiri SV, Szaefer F, Baev-Dubowska W. *Toxicol* 2003;189(3):199-209.
- [25] Samuelsen AB. *J Ethnopharmacol* 2000;71:1-21.
- [26] Yesilada E, Sezik E, Fujita T, Tanaka S, and Tabata M. *Phytother* 1993;7:263-265.
- [27] Galves M, Martin-Cordero C, Lopez-Larazo M, Cortes F, Ayusa MJ. *J Ethnopharmacol* 2003;88:125-130.
- [28] Oto G, Ekin S, Ozdemir H, Levent A, Berber I. *Toxicol Industr Health* 2011;28(4):334-342.
- [29] Levent A, Oto O, Ekin S, Berber İ. *Combinatorial Chemistry & High Throughput Screening* 2013;16(2):142-149.
- [30] Bnouham M, Merhfour FM, Ziyat A, Mekhfi H, Aziz M, Legssyer A. *Fitoterapia* 2003;74:677-681.
- [31] Laemmli UK. 1970;227:680-685.
- [32] Sambrook J, Fritsch EF, Maniatis T. *Analysis and cloning of eukaryotic DNA*. Cold Spring Harbor Laboratory Press, Plainiew, NY, 1989, pp. 9.1-9.62.
- [33] Oommen S, Anto RJ, Srinivas G, Karunakaran D. *Eur J Pharmacol* 2004;485:97-103.